#United States #New York #Levi & Korsinsky #Securities Fraud #BioAge Labs

Investors in BioAge Labs, Inc. Should Act Promptly

Levi & Korsinsky, LLP has issued an urgent call to investors of BioAge Labs, Inc. (NASDAQ: BIOA) concerning a class action lawsuit related to alleged securities fraud. The legal firm is advising affected shareholders to reach out as soon as possible, particularly before the deadline of March 10, 2025, to secure their rights.

Class Definition

The class action lawsuit targets shareholders who purchased BioAge's stocks tied to its registration statement regarding the company's initial public offering that took place around September 26, 2024. This action is in response to unexpected news surrounding BioAge's clinical trials that has caused significant financial repercussions for its investors.

What Happened?

On December 6, 2024, BioAge publicly announced the suspension of its STRIDES Phase 2 clinical trial for its leading drug candidate, azelaprag. The announcement, citing safety concerns over notably high liver transaminase levels observed in trial participants, took many by surprise. Just a few months prior, during its IPO, BioAge celebrated azelaprag’s potential benefits for patients undergoing obesity treatment with incretin drugs, which amplifies the shock from the sudden trial halt.

Consequently, the company's stock price plummeted from a robust $20.09 per share to a mere $4.65 the following day—an alarming drop that has left many shareholders in distress. Thus, the lawsuit seeks to redress financial losses suffered by these investors during this critical period.

Next Steps for Investors

If you have faced losses related to BioAge Labs shares during the outlined period, now is the time to act. You are eligible to request that the court appoint you as the lead plaintiff until March 10, 2025. Importantly, participation in the recovery process does not necessitate you to take on this role; being a class member alone may grant you compensation without any up-front costs.

No Financial Obligation

Levi & Korsinsky emphasizes that class members can seek compensation without bearing any out-of-pocket expenses or fees associated with legal representation. There is no obligation when you decide to reach out to them for assistance.

Why Choose Levi & Korsinsky?

With a seasoned team boasting over 20 years of experience in complex securities litigation, Levi & Korsinsky has successfully procured hundreds of millions of dollars for affected shareholders historically. Their commitment to pursuing justice for investors has consistently placed them among the leading securities litigation firms in the United States, as highlighted in the ISS Securities Class Action Services' Top 50 Report for seven consecutive years.

How to Reach Out

Investors affected by this situation can contact Levi & Korsinsky LLP directly. Reach out via email at [email protected] or call Joseph E. Levi, Esq. at (212) 363-7500 to get in touch with their team and begin the process of safeguarding your rights and interests in this matter.

Address: 33 Whitehall Street, 17th Floor, New York, NY 10004

In a time of uncertainty, it is crucial for investors in BioAge Labs to understand their rights and options, especially in light of this unfolding legal situation. Stay informed and take action to protect your investments.